{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:16:19Z","timestamp":1788509779602,"version":"build-2803163510"},"reference-count":38,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,7,27]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Type 2 diabetes mellitus (T2DM) imposes clinical and economic burdens worldwide, with the Kingdom of Saudi Arabia (KSA) reporting among the highest prevalence rates in the Middle East and North Africa (MENA) region. Despite national diabetes initiatives under Vision 2030 and recent guideline implementation, evidence on T2DM management among privately insured beneficiaries remains limited. This study aimed to provide one of the first real-world assessments of antidiabetic treatment patterns, therapy modifications, medication adherence and guideline-recommended glycaemic monitoring among privately insured patients with T2DM in KSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Longitudinal retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>A national claims-based analysis was conducted using the National Platform for Health Information Exchange Services (NPHIES), covering privately insured beneficiaries across KSA. The study period spanned from 1 September 2022 to 31 December 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Eligible participants were privately insured individuals aged \u226515 years with a diagnosis of T2DM, defined as having at least one medical claim of T2DM (International Classification of Diseases, 10th Revision, Australian Modification code E11) and continuous insurance enrolment for a minimum of 12 months (including \u2265180 days pre-index and \u2265180 days post-index). The index date was defined as the earliest observed antidiabetic prescription within the study window. A total of 187\u2009797 patients met the inclusion criteria and were included in the final analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The primary outcomes were antidiabetic real-world treatment patterns and therapy modifications, including treatment escalation, switching, early discontinuation and medication adherence. Secondary outcomes included guideline-recommended laboratory testing of glycaemic control for haemoglobin A1c (HbA1c), plasma glucose tests and oral glucose tolerance test. Claims were linked to the Council of Health Insurance\u2019s internal product dictionary using the NPHIES product\/service code to retrieve the standardised product name and activity type. Data extraction used Structured Query Language-based queries and Python transformation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients had a mean age of 53.7 years, while T2DM rates reached 47.4 per 1000 insured men and 43.8 per 1000 insured women. Combination therapy accounted for 29.4% of initial treatment regimens among eligible patients with T2DM. Biguanide monotherapy users exhibited switching and escalation rates of 9% and 7%,\u2009respectively, while 35% of sulfonylurea users exhibited escalation. Treatment discontinuation was observed in 22% of users of combination therapies, 22% of SGLT2 inhibitor users and 19% of sulfonylurea users. The medication possession ratio was 0.87 for insulin users. Regarding laboratory monitoring, 61% of patients had at least one glycaemic test 6 months prior to therapy initiation. Laboratory testing reached 73% following therapy initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The Saudi experience suggests that integrated national claims platforms, supported by standardised coding and e-prescribing, can play a critical role in advancing real-world evidence generation and informing diabetes management strategies in KSA and across MENA health systems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-118711","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:30:27Z","timestamp":1786361427000},"page":"e118711","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns and adherence among privately insured patients with type 2 diabetes in Saudi Arabia: a retrospective cohort study using national claims data"],"prefix":"10.1136","volume":"16","author":[{"given":"Shabab","family":"Alghamdi","sequence":"first","affiliation":[{"name":"Council of Health Insurance, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Abdulrahman","family":"Aljuffali","sequence":"additional","affiliation":[{"name":"Council of Health Insurance, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M","family":"AlDammas","sequence":"additional","affiliation":[{"name":"Council of Health Insurance, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebras","family":"Abu Alhamayel","sequence":"additional","affiliation":[{"name":"Council of Health Insurance, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Jumaah","sequence":"additional","affiliation":[{"name":"Itkan Consulting, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0327-0604","authenticated-orcid":false,"given":"Mirna","family":"Matni","sequence":"additional","affiliation":[{"name":"Center of Clinical, Health Economics, and Outcomes Research, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Barhoun","sequence":"additional","affiliation":[{"name":"Center of Clinical, Health Economics, and Outcomes Research, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed Mastour","family":"Alshahrani","sequence":"additional","affiliation":[{"name":"King Khalid University, Abha, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Alagil","sequence":"additional","affiliation":[{"name":"Council of Health Insurance, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"2026090400402575000_16.8.e118711.1","doi-asserted-by":"crossref","unstructured":"GBD Diabetes Collaborators . Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Lond Engl 2021;203\u201334. doi:10.1016\/S0140-6736(23)01301-6","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"2026090400402575000_16.8.e118711.2","unstructured":"World Health Organization. who.int [Internet] . Noncommunicable diseases. 2025. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/noncommunicable-diseases"},{"key":"2026090400402575000_16.8.e118711.3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac034"},{"key":"2026090400402575000_16.8.e118711.4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/14737167.2020.1782748","article-title":"Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses","volume":"21","author":"Alzaid","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2026090400402575000_16.8.e118711.5","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-020-05897-w","article-title":"Costs and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studies","volume":"20","author":"Stegbauer","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"2026090400402575000_16.8.e118711.6","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-018-1019-z","article-title":"Availability and affordability of essential medicines: implications for global diabetes treatment","volume":"18","author":"Beran","year":"2018","journal-title":"Curr Diab Rep"},{"key":"2026090400402575000_16.8.e118711.7","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-019-1125-6","article-title":"Diabetes in the Middle East: government health care policies and strategies that address the growing diabetes prevalence in the Middle East","volume":"19","author":"Al Busaidi","year":"2019","journal-title":"Curr Diab Rep"},{"key":"2026090400402575000_16.8.e118711.8","unstructured":"International Diabetes Federation. Diabetes Atlas [Internet] . Middle East and North Africa diabetes regional report 2000\u20132050. 2025. Available: https:\/\/diabetesatlas.org\/data-by-location\/region\/middle-east-and-north-africa\/"},{"key":"2026090400402575000_16.8.e118711.9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pcd.2020.01.003","article-title":"Prevalence of type 2 diabetes in Middle East: systematic review and meta-analysis","volume":"14","author":"Kalan Farmanfarma","year":"2020","journal-title":"Prim Care Diabetes"},{"key":"2026090400402575000_16.8.e118711.10","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.jsps.2020.09.018","article-title":"The impact of diabetes mellitus on health-related quality of life in Saudi Arabia","volume":"28","author":"Almasri","year":"2020","journal-title":"Saudi Pharm J"},{"key":"2026090400402575000_16.8.e118711.11","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2147\/PPA.S265126","article-title":"Patient-reported outcomes and impact of type 2 diabetes: a cross-sectional study in the Kingdom of Saudi Arabia","volume":"14","author":"Gelhorn","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"2026090400402575000_16.8.e118711.12","unstructured":"Saudi National Diabetes Center (SNDC) . Saudi diabetes clinical practice guidelines. 2021. Available: https:\/\/www.moh.gov.sa\/Ministry\/MediaCenter\/Publications\/Documents\/Saudi-Diabetes-Clinical-Practice-Guidelines.pdf"},{"key":"2026090400402575000_16.8.e118711.13","doi-asserted-by":"crossref","unstructured":"Al-Sofiani ME , Al-Murashi AM , Al-Agil NA , et al . Diabetes technology in Saudi Arabia: current status and future directions. J Diabetes Sci Technol 2025.:19322968251370756. doi:10.1177\/19322968251370756","DOI":"10.1177\/19322968251370756"},{"key":"2026090400402575000_16.8.e118711.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5"},{"key":"2026090400402575000_16.8.e118711.15","doi-asserted-by":"crossref","unstructured":"Aristiz\u00e1bal-Colorado D , Corredor-Rengifo D , Sierra-Castillo S , et al . A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists \u2013 a comprehensive review. Front Endocrinol 2025;16. doi:10.3389\/fendo.2025.1605746","DOI":"10.3389\/fendo.2025.1605746"},{"key":"2026090400402575000_16.8.e118711.16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/DHPS.S496619","article-title":"Comparing out-of-pocket costs and health-related quality of life between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes","volume":"17","author":"Hu","year":"2025","journal-title":"Drug Healthc Patient Saf"},{"key":"2026090400402575000_16.8.e118711.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273836","article-title":"Cost of cardiovascular diseases and renal complications in people with type 2 diabetes mellitus in the Kingdom of Saudi Arabia: A retrospective analysis of claims database","volume":"17","author":"Al-Jedai","year":"2022","journal-title":"PLoS One"},{"key":"2026090400402575000_16.8.e118711.18","unstructured":"International Trade Administration. trade.gov [Internet] . Saudi Arabia country commercial guide. 2024. Available: https:\/\/www.trade.gov\/country-commercial-guides\/saudi-arabia-healthcare"},{"key":"2026090400402575000_16.8.e118711.19","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.dsx.2021.04.003","article-title":"Pharmacological treatment of type 2 diabetes in Saudi Arabia: a consensus statement from the Saudi Society of Endocrinology and Metabolism (SSEM)","volume":"15","author":"Al-Sofiani","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"2026090400402575000_16.8.e118711.20","unstructured":"Council of Health Insurance (CHI) . Insurance Drug Formulary (IDF).Available: https:\/\/www.chi.gov.sa\/en\/Rules\/Documents\/Insurance%20Drug%20Formulary%20(IDF).pdf#:~:text=Medications%20Co"},{"key":"2026090400402575000_16.8.e118711.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"key":"2026090400402575000_16.8.e118711.22","unstructured":"NPHIES . Healthcare financial services IG edition 1 v1.0.0. 2025. Available: https:\/\/portal.nphies.sa\/ig\/index.html"},{"key":"2026090400402575000_16.8.e118711.23","unstructured":"Council of Health Insurance. chi.gov [Internet] . Statistics & indicators. 2025. Available: https:\/\/www.chi.gov.sa\/en\/open-data\/Pages\/Indicators-and-statistics.aspx"},{"key":"2026090400402575000_16.8.e118711.24","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S004"},{"key":"2026090400402575000_16.8.e118711.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-024-03324-z","article-title":"Medication adherence in patients with type 2 diabetes after disability onset: a difference-in-differences analysis using nationwide data","volume":"22","author":"Chen","year":"2024","journal-title":"BMC Med"},{"key":"2026090400402575000_16.8.e118711.26","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology . ATC\/DDD Index 2025 [Internet]. 2025. Available: https:\/\/atcddd.fhi.no\/atc_ddd_index\/"},{"key":"2026090400402575000_16.8.e118711.27","unstructured":"pqaalliance.org [Internet] . Adherence PQA adherence measures. 2025. Available: https:\/\/www.pqaalliance.org\/adherence-measures"},{"key":"2026090400402575000_16.8.e118711.28","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-022-00785-1","article-title":"Adherence and persistence rates of major antidiabetic medications: a review","volume":"14","author":"Lee","year":"2022","journal-title":"Diabetol Metab Syndr"},{"key":"2026090400402575000_16.8.e118711.29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2016.09.777","article-title":"Comparative analysis of medication possession ratio measures for adherence to single-medication","volume":"19","author":"\u00c1gh","year":"2016","journal-title":"Value in Health"},{"key":"2026090400402575000_16.8.e118711.30","unstructured":"studylib.net [Internet] . Data management &amp; personal data protection standards version 1.5. 2021. Available: https:\/\/studylib.net\/doc\/26020832\/policiesen001-eng"},{"key":"2026090400402575000_16.8.e118711.31","doi-asserted-by":"crossref","first-page":"103224","DOI":"10.1016\/j.dsx.2025.103224","article-title":"Prevalence of cardiovascular risk and atherosclerotic cardiovascular disease in people with type 2 diabetes in the United Arab Emirates: results from the prevalence of atherosclerotic cardiovascular disease in patients with type 2 diabetes across Middle East and African countries (PACT-MEA) study","volume":"19","author":"Awadi","year":"2025","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"2026090400402575000_16.8.e118711.32","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1085928","article-title":"Health-related quality of life of Kuwaiti adults living with diabetes","volume":"11","author":"Alowayesh","year":"2023","journal-title":"Front Public Health"},{"key":"2026090400402575000_16.8.e118711.33","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2025.100809","article-title":"Initiation of type 2 diabetes mellitus medications in the NGHA healthcare system in Saudi Arabia: contemporary trends","volume":"103","author":"Alyabsi","year":"2025","journal-title":"Curr Ther Res Clin Exp"},{"key":"2026090400402575000_16.8.e118711.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2022-002995","article-title":"Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada","volume":"10","author":"Carney","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026090400402575000_16.8.e118711.35","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000767","article-title":"Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands","volume":"8","author":"van den Heuvel","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026090400402575000_16.8.e118711.36","first-page":"165","article-title":"Comparing medication adherence and persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or sulfonylureas","volume":"10","author":"Bell","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"2026090400402575000_16.8.e118711.37","doi-asserted-by":"crossref","first-page":"111770","DOI":"10.1016\/j.diabres.2024.111770","article-title":"Treatment modification patterns of glucose-lowering agents in Saudi Arabia: A retrospective real-world data analysis","volume":"214","author":"Alfakhri","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"2026090400402575000_16.8.e118711.38","doi-asserted-by":"crossref","unstructured":"ElSayed NA , Aleppo G , Aroda VR , et al . Summary of revisions: standards of care in diabetes\u20142023. Diabetes Care 2023;S5\u20139. doi:10.2337\/dc23-ad08","DOI":"10.2337\/dc23-Srev"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-118711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:40:39Z","timestamp":1788507639000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-118711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,10]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bmjopen-2026-118711"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-118711","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}